Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

@article{James2013MitomycinOC,
  title={Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.},
  author={R Darwent James and Robert Glynne-Jones and Holly B. Meadows and David Cunningham and Arthur Sun Myint and Mark P. Saunders and Timothy S. Maughan and Alexander C. McDonald and Sharadah Essapen and Martin D Leslie and Stephen Falk and Charles L. Wilson and Simon William Gollins and Rubina Begum and Jonathan A Ledermann and Latha Kadalayil and Harm J. T. Rutten},
  journal={The Lancet. Oncology},
  year={2013},
  volume={14 6},
  pages={
          516-24
        }
}
BACKGROUND Chemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival. METHODS In this 2 × 2 factorial trial, we enrolled patients with histologically confirmed squamous… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 136 CITATIONS, ESTIMATED 34% COVERAGE

Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer

  • Cancer Chemotherapy and Pharmacology
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.

  • Annals of the Royal College of Surgeons of England
  • 2019
VIEW 4 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Evolution and Management of Treatment-Related Toxicity in Anal Cancer.

  • Surgical oncology clinics of North America
  • 2017
VIEW 7 EXCERPTS
CITES RESULTS, METHODS & BACKGROUND
HIGHLY INFLUENCED

Treatment of the Primary Tumor in Anal Canal Cancers.

  • Surgical oncology clinics of North America
  • 2017
VIEW 8 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.

  • Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2015
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Improved oncological treatment of anal cancer

VIEW 4 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey.

  • The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 20 Highly Influenced Citations

  • Averaged 24 Citations per year from 2017 through 2019